Please login to the form below

IQWiG

This page shows the latest IQWiG news and features for those working in and with pharma, biotech and healthcare.

Blind man's buff

In IQWIG’s words, ‘the rhetoric of novelty and innovation creates an assumption that new products are better than existing ones’. ... The IQWIG evidence tells us that our industry is wasteful of its innovative resources.

Latest news

Diurnal files adrenal insufficiency drug Alkindi in US

Care (IQWiG) concluded it had not been proven to be superior to generic hydrocortisone.
Resurgent Diurnal raises £5.4m for twin product filings

IQWiG) concluded it had not been proven to be superior to generic hydrocortisone.
Transforming access in rare diseases

From IQWiG in Germany to the HAS in France and the Pharmaceutical Benefits Advisory Committee in Australia, the reality we face is that all technology assessment organisations work in slightly different
Focus on value: A prescription for pharma

The pricing debate demands a common language to be developed
NICE backs use of AZ's Brilique as maintenance therapy

A similar verdict was reached by NICE's German counterpart IQWiG earlier this year.

More from news
Approximately 23 fully matching, plus 45 partially matching documents found.

Latest Intelligence

The gold standard of scientific evidence

PBAC appraisals, 64% of NICE appraisals and all IQWiG appraisals relied on RCT-based evidence.
Digital disruption

best patient outcomes - information that would probably come in very handy for submissions to the likes of NICE or IQWiG.
Stepping up to payer-driven market access

Combined with the demanding - and often less familiar - requirements of the GBA and IQWIG in Germany and other agencies in Europe, these changes make early understanding of the payer environment critical
The price is right?

IQWiG evaluations often focus on different patient populations from those used in the clinical trials. ... The dynamic between the G-BA and IQWiG makes pricing and reimbursement an extremely complex process.”.
Biosimilars - the same, but different?

After regulatory clarity, the focus will certainly move to health technology assessment bodies, such as Germany's IQWiG and the UK's NICE, if biosimilars' place in clinical practice is to ... For its part IQWiG has yet to assess any biosimilar products.

More from intelligence
Approximately 4 fully matching, plus 17 partially matching documents found.

Latest from PMHub

Oncology drugs under AMNOG

Usually the G-BA also seeks the advice of expert Health Technology Assessment (HTA) body IQWiG (the Institute for Quality and Efficiency in Healthcare), to determine the level of added benefit ... The G-BA and IQWiG restricted these options to therapies

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior / Principal Medical Writer – Medical Education - UK &...: Excellent Salary and Benefits on offer

Experienced / Senior Medical Writer - MedComms - Cardiff - Wales: Excellent Salary and Benefits on offer

Senior Medical Writer – Leading Medical Communications Agency – ...: Highly Competitive Remuneration Package

Graduate / Entry Level Opportunities – Medical Communications – ...: Highly Competitive Remuneration Package

Scientific Director - Medical Communications Agency - New York: Excellent Remuneration Package

Senior Medical Writer– Medical Education – Oxford - London: Excellent Remuneration Package

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Programme Manager / Programme Director – Medical Education - Buc...: Salary TBC

Scientific Director - Medical Education - Cheshire & London ...: Excellent Remuneration Package

Account Director, Medical Education: Salary TBC

Associate Medical Writer / Entry Level Medical Writer - Medical ...: DOE

Senior Medical Writer: Salary TBC

Account Manager / Senior Account Manager - Creative MedComms - C...: Excellent Remuneration

Account Director – Cheshire based Medical Communications Agency...: D.O.E

Subscribe to our email news alerts

PMHub

Add my company

Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

The 2019 CPhI Pharma Index Report: Examining this year’s industry performance...
Five key trends in precision and personalised healthcare: Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications: Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...